MX2011006843A - Dihidropiridona-amidas como moduladores de p2x7. - Google Patents

Dihidropiridona-amidas como moduladores de p2x7.

Info

Publication number
MX2011006843A
MX2011006843A MX2011006843A MX2011006843A MX2011006843A MX 2011006843 A MX2011006843 A MX 2011006843A MX 2011006843 A MX2011006843 A MX 2011006843A MX 2011006843 A MX2011006843 A MX 2011006843A MX 2011006843 A MX2011006843 A MX 2011006843A
Authority
MX
Mexico
Prior art keywords
modulators
compounds
dihydropyridone
amides
dihydropyridone amides
Prior art date
Application number
MX2011006843A
Other languages
English (en)
Inventor
Jacob Berger
Keith Adrian Murray Walker
Shu-Hai Zhao
Christine E Brotherton-Pleiss
Francisco Javier Lopez-Tapia
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2011006843A publication Critical patent/MX2011006843A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compuestos de la fórmula I: (ver fórmula (I)) o sales farmacéuticamente aceptables de los mismos, en la que m, n, p, q, R1, R2, R3, R4, R5 y R6 tienen los significados aquí definidos. Se describen también métodos de obtención de los compuestos y de uso de los compuestos para el tratamiento de enfermedades asociadas con el receptor purinérgico de P2X7.
MX2011006843A 2008-12-23 2009-12-14 Dihidropiridona-amidas como moduladores de p2x7. MX2011006843A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20346208P 2008-12-23 2008-12-23
PCT/EP2009/067060 WO2010072607A1 (en) 2008-12-23 2009-12-14 Dihydropyridone amides as p2x7 modulators

Publications (1)

Publication Number Publication Date
MX2011006843A true MX2011006843A (es) 2011-08-04

Family

ID=41800777

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011006843A MX2011006843A (es) 2008-12-23 2009-12-14 Dihidropiridona-amidas como moduladores de p2x7.

Country Status (14)

Country Link
US (1) US8163929B2 (es)
EP (1) EP2382202A1 (es)
JP (1) JP5405592B2 (es)
KR (1) KR101370185B1 (es)
CN (1) CN102264722B (es)
AR (1) AR074817A1 (es)
AU (1) AU2009331669B2 (es)
BR (1) BRPI0924059A2 (es)
CA (1) CA2745952A1 (es)
IL (1) IL213346A (es)
MX (1) MX2011006843A (es)
SG (1) SG172385A1 (es)
TW (1) TW201028392A (es)
WO (1) WO2010072607A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2783236C (en) * 2009-12-08 2020-03-10 Vanderbilt University Improved methods and compositions for vein harvest and autografting
DK3239134T3 (da) 2013-01-31 2021-02-22 Vertex Pharma Pyridonamider som modulatorer af natriumkanaler
PL3640241T3 (pl) * 2013-10-18 2022-12-05 Celgene Quanticel Research, Inc. Inhibitory bromodomeny
AR098436A1 (es) * 2013-11-19 2016-05-26 Actelion Pharmaceuticals Ltd Compuestos tricíclicos de piperidina
LT3080134T (lt) 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
WO2015099107A1 (ja) 2013-12-26 2015-07-02 塩野義製薬株式会社 含窒素６員環誘導体およびそれらを含有する医薬組成物
CN104926801B (zh) * 2014-03-22 2019-06-04 浙江大学 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用
JP6358639B2 (ja) 2015-04-24 2018-07-18 塩野義製薬株式会社 ６員複素環誘導体およびそれらを含有する医薬組成物
MX2019004107A (es) 2016-10-17 2019-08-05 Shionogi & Co Derivado heterociclico nitrogenado biciclico y composicion farmaceutica que lo contiene.
ES2927712T3 (es) 2017-05-16 2022-11-10 Vertex Pharma Amidas deuteradas de piridona y profármacos de las mismas como moduladores de canales de sodio
US20190343817A1 (en) 2018-02-12 2019-11-14 Vertex Pharmaceuticals Incorporated Method of treating pain
TW202128675A (zh) 2019-12-06 2021-08-01 美商維泰克斯製藥公司 作為鈉通道調節劑之經取代四氫呋喃
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2051705A1 (en) * 1990-06-19 1991-12-20 Kiyoaki Katano Pyridine derivatives having angiotensin ii antagonism
CZ403592A3 (en) 1992-02-20 1993-12-15 Hoechst Ag Arylcarbonylaminoalkyldihydrooxopyridines, process of their preparation and their use
DE4206045A1 (de) 1992-02-27 1993-09-02 Bayer Ag Sulfonylbenzyl substituierte pyridone
DE4215587A1 (de) 1992-05-12 1993-11-18 Bayer Ag Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone
CN1291892A (zh) 1998-01-27 2001-04-18 阿温蒂斯药物制品公司 取代的氧代氮杂杂环基因子Xa抑制剂
DE10010430A1 (de) * 2000-03-03 2001-09-06 Bayer Ag Substituierte 5-Ethyl-dihydropyridazinone und ihre Verwendung
NZ522773A (en) 2000-06-12 2005-06-24 Eisai Co Ltd 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
JP2005170790A (ja) 2002-01-09 2005-06-30 Ajinomoto Co Inc Ｎ−アルキルスルフォニル置換アミド誘導体
US7592357B2 (en) * 2004-02-20 2009-09-22 Smithkline Beecham Corporation Compounds
FR2878528B1 (fr) 2004-11-29 2008-05-16 Aventis Pharma Sa 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
RS51822B (en) 2005-04-04 2012-02-29 Eisai R. &D. Management Co. Ltd. DIHYDROPYRIDINE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND Dementia
EP1875912A4 (en) 2005-04-08 2008-06-04 Eisai R&D Man Co Ltd MEANS OF TREATING UNWILLING MOVEMENTS
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors

Also Published As

Publication number Publication date
KR20110086868A (ko) 2011-08-01
TW201028392A (en) 2010-08-01
SG172385A1 (en) 2011-08-29
AU2009331669A1 (en) 2011-06-23
IL213346A (en) 2015-08-31
KR101370185B1 (ko) 2014-03-05
BRPI0924059A2 (pt) 2015-07-07
IL213346A0 (en) 2011-07-31
CN102264722A (zh) 2011-11-30
WO2010072607A1 (en) 2010-07-01
AR074817A1 (es) 2011-02-16
EP2382202A1 (en) 2011-11-02
JP5405592B2 (ja) 2014-02-05
US20100160384A1 (en) 2010-06-24
US8163929B2 (en) 2012-04-24
AU2009331669B2 (en) 2015-10-15
CN102264722B (zh) 2014-04-02
JP2012513437A (ja) 2012-06-14
CA2745952A1 (en) 2010-07-01
AU2009331669A8 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
MX2011006843A (es) Dihidropiridona-amidas como moduladores de p2x7.
MX2012002387A (es) Aminas de triazol fusionadas como moduladores p2x7.
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
MX349556B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
MX348606B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2).
MX2009004662A (es) Compuestos de pirazolina como antagonistas receptores de mineralocorticoides.
MX356644B (es) Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
MX348920B (es) Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
MY151986A (en) Adamantyl diamide derivatives and uses of same
MX2010006230A (es) Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
EA201291220A1 (ru) Производные аминопиримидина в качестве модуляторов lrrk2
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
TW200740773A (en) Diaminopyrimidines as P2X3 and P2X2/3 modulators
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
MX2009003316A (es) Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
HRP20130614T1 (en) Novel pyrazole-substituted arylamides
MX358172B (es) Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MY146506A (en) Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2010009644A (es) Derivados piridin-2-ilo como agentes inmunomoduladores.
MX2010004487A (es) Derivados lactamicos sustituidos y sus usos para glaucoma e hipertension ocular.

Legal Events

Date Code Title Description
FG Grant or registration